Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table A20–2 Disease Scenarios for RSV

 

No. of Cases

% of Cases

Committee HUI Values

Duration (years)

AGE<1

 

Total Deaths

300

 

Total Cases

1,000,000

 

Upper Respiratory

pharyngitis, otitis media

600,000

60.00%

0.90

0.0192 (7 days)

Bronchiolitis/pneumonia

outpatient only

340,000

34.00%

0.75

0.0274 (10 days)

Bronchiolitis/pneumonia

60,000

6.00%

 

inpatient

 

0.50

0.0192 (7 days)

outpatient

 

0.75

0.0082 (3 days)

AGE 1–4

 

Total Deaths (from acute infection)

200

 

Total Cases

2,000,000

 

Upper Respiratory

pharyngitis, otitis media

1,200,000

60.00%

0.90

0.0192 (7 days)

Bronchiolitis/pneumonia

outpatient only

760,000

38.00%

0.75

0.0274 (10 days)

Bronchiolitis/pneumonia

40,000

2.00%

 

inpatient

 

0.50

0.0192 (7 days)

outpatient

 

0.75

0.0082 (3 days)

AGE 5+

 

Total Deaths (from acute infection)

20

 

Total Cases

2,000,000

 

Upper Respiratory

pharyngitis, otitis media

1,600,000

80.00%

0.90

0.0192 (7 days)

Bronchiolitis/pneumonia

outpatient only

396,000

19.80%

0.75

0.0274 (10 days)

Bronchiolitis/pneumonia

4,000

0.20%

 

inpatient

 

0.50

0.0192 (7 days)

outpatient

 

0.75

0.0082 (7 days)

VACCINE PROGRAM CONSIDERATIONS

Target Population

For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is all adolescent girls (age 12 years) and all infants. For this example, the committee included adolescent girls in order to induce immunity that would protect the neonate. Infants are immunized to protect against disease after 1 year of age. It was assumed that 50% of adolescent females and 90% of infants would utilize the vaccine.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement